Cargando...
Agents to treat BRAF-mutant lung cancer
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be more aggressive and resistant to chemotherapy...
Gardado en:
| Publicado en: | Drugs Context |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioExcel Publishing Ltd
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6419923/ https://ncbi.nlm.nih.gov/pubmed/30899313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212566 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|